NASDAQ:QTNT - Quotient Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.80 +0.26 (+3.98 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$6.54
Today's Range$6.62 - $7.09
52-Week Range$2.78 - $7.73
Volume976,700 shs
Average Volume482,323 shs
Market Capitalization$305.90 million
P/E Ratio-2.25
Dividend YieldN/A
Beta-0.02

About Quotient (NASDAQ:QTNT)

Quotient logoQuotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It also develops, manufactures, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to donor collection agencies and testing laboratories, hospitals, independent patient testing laboratories, reference laboratories, blood banking operations, and other diagnostic companies, as well as to original equipment manufacturers. Quotient Limited was founded in 2007 and is based in Penicuik, the United Kingdom.

Receive QTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QTNT
CUSIPN/A
Phone011-41-22-716-9800

Debt

Debt-to-Equity Ratio22.54
Current Ratio2.34
Quick Ratio1.65

Price-To-Earnings

Trailing P/E Ratio-2.25
Forward P/E Ratio-3.29
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.23 million
Price / Sales13.95
Cash FlowN/A
Price / CashN/A
Book Value($0.64) per share
Price / Book-10.63

Profitability

EPS (Most Recent Fiscal Year)($3.02)
Net Income$-85,060,000.00
Net Margins-342.23%
Return on EquityN/A
Return on Assets-64.90%

Miscellaneous

Employees393
Outstanding Shares45,590,000

Quotient (NASDAQ:QTNT) Frequently Asked Questions

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

How were Quotient's earnings last quarter?

Quotient (NASDAQ:QTNT) announced its earnings results on Monday, May, 22nd. The company reported ($0.69) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.07. The business had revenue of $5.53 million for the quarter, compared to the consensus estimate of $4.30 million. View Quotient's Earnings History.

When is Quotient's next earnings date?

Quotient is scheduled to release their next quarterly earnings announcement on Tuesday, May, 29th 2018. View Earnings Estimates for Quotient.

What price target have analysts set for QTNT?

2 brokers have issued 1 year price targets for Quotient's stock. Their predictions range from $10.00 to $13.00. On average, they expect Quotient's share price to reach $11.50 in the next year. View Analyst Ratings for Quotient.

Who are some of Quotient's key competitors?

Who are Quotient's key executives?

Quotient's management team includes the folowing people:
  • Mr. Jeremy Stackawitz, Pres (Age 43)
  • Mr. Edward Farrell, Pres (Age 48)
  • Mr. Christopher J. Lindop, Chief Financial Officer (Age 60)
  • Mr. Franz Walt, Interim CEO & Director
  • Mr. John Allan, Corp. Sr. VP & CTO

Has Quotient been receiving favorable news coverage?

Press coverage about QTNT stock has trended somewhat positive on Saturday, according to Accern. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Quotient earned a daily sentiment score of 0.16 on Accern's scale. They also assigned press coverage about the company an impact score of 46.82 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Quotient's major shareholders?

Quotient's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Highbridge Capital Management LLC (4.40%), BlackRock Inc. (2.62%), Prosight Management LP (1.50%), Knott David M (0.35%), Opaleye Management Inc. (0.13%) and Birchview Capital LP (0.09%). Company insiders that own Quotient stock include Brian Mcdonough, D J Paul E Cowan, Jeremy Stackawitz, L John Wilkerson, Life Sciences Maste Perceptive, Prondzynski Heino Von and Stephen Unger. View Institutional Ownership Trends for Quotient.

Which major investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Prosight Management LP, Birchview Capital LP and BlackRock Inc.. View Insider Buying and Selling for Quotient.

Which major investors are buying Quotient stock?

QTNT stock was purchased by a variety of institutional investors in the last quarter, including Knott David M, Opaleye Management Inc. and The Manufacturers Life Insurance Company . Company insiders that have bought Quotient stock in the last two years include Brian Mcdonough, D J Paul E Cowan, L John Wilkerson, Life Sciences Maste Perceptive and Prondzynski Heino Von. View Insider Buying and Selling for Quotient.

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $6.80.

How big of a company is Quotient?

Quotient has a market capitalization of $305.90 million and generates $22.23 million in revenue each year. The company earns $-85,060,000.00 in net income (profit) each year or ($3.02) on an earnings per share basis. Quotient employs 393 workers across the globe.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.


MarketBeat Community Rating for Quotient (QTNT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  253
MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote "Outperform" if you believe QTNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Quotient (NASDAQ:QTNT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Quotient in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 69.12%. The high price target for QTNT is $13.00 and the low price target for QTNT is $10.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$11.50$12.50$12.50
Price Target Upside: 69.12% upside144.16% upside144.62% upside144.62% upside

Quotient (NASDAQ:QTNT) Consensus Price Target History

Price Target History for Quotient (NASDAQ:QTNT)

Quotient (NASDAQ:QTNT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2018BTIG ResearchSet Price TargetBuy$10.00MediumView Rating Details
11/1/2017Jefferies GroupLower Price TargetBuy$15.00 ➝ $13.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Quotient (NASDAQ:QTNT) Earnings History and Estimates Chart

Earnings by Quarter for Quotient (NASDAQ:QTNT)

Quotient (NASDAQ:QTNT) Earnings Estimates

2018 EPS Consensus Estimate: ($2.21)
2019 EPS Consensus Estimate: ($1.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.56)($0.56)($0.56)
Q2 20181($0.59)($0.59)($0.59)
Q3 20181($0.55)($0.55)($0.55)
Q4 20181($0.51)($0.51)($0.51)
Q1 20191($0.34)($0.34)($0.34)
Q2 20191($0.15)($0.15)($0.15)
Q3 20191($0.33)($0.33)($0.33)
Q4 20191($0.32)($0.32)($0.32)

Quotient (NASDAQ QTNT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2018Q4($0.51)N/AView Earnings Details
2/5/2018Q3 2018($0.55)($0.47)$5.20 million$5.86 millionViewN/AView Earnings Details
10/30/2017Q2 2018($0.59)($0.58)$5.30 million$5.91 millionViewN/AView Earnings Details
8/7/2017Q1 2018($0.55)($0.55)$5.70 million$6.83 millionViewListenView Earnings Details
5/22/2017Q4($0.76)($0.69)$4.30 million$5.53 millionViewN/AView Earnings Details
2/6/201712/31/2016($0.56)($1.06)$4.50 million$4.84 millionViewListenView Earnings Details
10/31/2016Q2 2017($0.64)($0.62)$5.90 million$6.14 millionViewN/AView Earnings Details
8/8/2016Q1 2017($0.71)($0.64)$5.70 million$5.72 millionViewN/AView Earnings Details
5/23/2016Q4($0.59)($0.41)$5.00 million$5.05 millionViewN/AView Earnings Details
2/8/2016Q316($0.76)($0.48)$4.06 million$4.35 millionViewN/AView Earnings Details
11/2/2015Q216($0.80)($0.25)$4.42 million$4.27 millionViewN/AView Earnings Details
8/3/2015Q116($0.67)($0.60)$4.90 million$4.85 millionViewN/AView Earnings Details
5/18/2015Q415($0.52)($0.77)$4.39 million$3.90 millionViewN/AView Earnings Details
2/2/2015($0.68)($0.51)$4.26 million$4.06 millionViewN/AView Earnings Details
11/3/2014($0.58)($0.82)$4.62 million$4.53 millionViewN/AView Earnings Details
8/4/2014Q1 2015($0.48)($0.39)$5.92 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Quotient (NASDAQ:QTNT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Quotient (NASDAQ QTNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 29.00%
Institutional Ownership Percentage: 61.55%
Insider Trading History for Quotient (NASDAQ:QTNT)
Institutional Ownership by Quarter for Quotient (NASDAQ:QTNT)

Quotient (NASDAQ QTNT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2018Life Sciences Maste PerceptiveMajor ShareholderBuy450,000$6.45$2,902,500.00View SEC Filing  
2/21/2018Prondzynski Heino VonDirectorBuy12,000$4.28$51,360.00View SEC Filing  
2/8/2018Brian McdonoughDirectorBuy10,000$3.87$38,700.0047,747View SEC Filing  
10/18/2017D J Paul E CowanInsiderSell100,000$4.64$464,000.0026,666View SEC Filing  
10/17/2017D J Paul E CowanInsiderSell45,000$4.55$204,750.0026,666View SEC Filing  
10/16/2017D J Paul E CowanInsiderSell30,197$4.92$148,569.2426,666View SEC Filing  
9/18/2017D J Paul E CowanInsiderSell100,000$4.41$441,000.0026,666View SEC Filing  
8/21/2017D J Paul E CowanInsiderSell45,540$3.52$160,300.8026,666View SEC Filing  
8/17/2017D J Paul E CowanInsiderSell54,460$4.06$221,107.6026,666View SEC Filing  
7/20/2017D J Paul E CowanInsiderSell9,420$6.11$57,556.2026,666View SEC Filing  
7/19/2017D J Paul E CowanInsiderSell90,580$6.39$578,806.2026,666View SEC Filing  
7/18/2017D J Paul E CowanInsiderSell20,580$6.29$129,448.2026,666View SEC Filing  
7/17/2017D J Paul E CowanInsiderSell45,032$6.57$295,860.2426,666View SEC Filing  
8/3/2016D J Paul E CowanInsiderBuy45,455$5.50$250,002.5026,666View SEC Filing  
8/3/2016L John WilkersonDirectorBuy180,000$5.50$990,000.00View SEC Filing  
6/9/2016Jeremy StackawitzPresidentSell15,000$10.00$150,000.00127,741View SEC Filing  
6/3/2016Stephen UngerCFOSell14,484$9.99$144,695.16View SEC Filing  
6/2/2016Stephen UngerCFOSell8,516$10.49$89,332.8421,497View SEC Filing  
2/10/2016Zubeen ShroffDirectorBuy222,222$9.00$1,999,998.00View SEC Filing  
6/2/2015Sarah A OconnorDirectorBuy10,000$15.50$155,000.00View SEC Filing  
3/13/2015Stephen UngerInsiderBuy3,000$15.00$45,000.00View SEC Filing  
3/3/2015Jeremy StackawitzPresidentSell30,000$16.80$504,000.00View SEC Filing  
3/2/2015Jeremy StackawitzPresidentSell4,012$16.88$67,722.56View SEC Filing  
2/17/2015Jeremy StackawitzPresidentSell14,140$17.00$240,380.00View SEC Filing  
11/28/2014Galen Partners V LpMajor ShareholderBuy157,895$9.50$1,500,002.50View SEC Filing  
8/7/2014Stephen UngerCFOBuy3,000$9.13$27,390.00View SEC Filing  
4/30/2014Galen Partners V LpMajor ShareholderBuy312,500$8.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Quotient (NASDAQ QTNT) News Headlines

Source:
DateHeadline
Insider Buying: Quotient (QTNT) Major Shareholder Acquires 450,000 Shares of StockInsider Buying: Quotient (QTNT) Major Shareholder Acquires 450,000 Shares of Stock
www.americanbankingnews.com - May 24 at 7:14 PM
Celldex Therapeutics (CLDX) vs. Quotient (QTNT) Financial ComparisonCelldex Therapeutics (CLDX) vs. Quotient (QTNT) Financial Comparison
www.americanbankingnews.com - May 24 at 5:17 AM
Quotient (QTNT) Set to Announce Earnings on TuesdayQuotient (QTNT) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 22 at 2:28 AM
Quotient (QTNT) Given a $10.00 Price Target by BTIG Research AnalystsQuotient (QTNT) Given a $10.00 Price Target by BTIG Research Analysts
www.americanbankingnews.com - May 21 at 12:35 PM
Brokerages Expect Quotient (QTNT) to Announce ($0.51) Earnings Per ShareBrokerages Expect Quotient (QTNT) to Announce ($0.51) Earnings Per Share
www.americanbankingnews.com - May 19 at 3:22 AM
Quotient (QTNT) Downgraded by ValuEngineQuotient (QTNT) Downgraded by ValuEngine
www.americanbankingnews.com - May 18 at 11:20 PM
Analyzing Celldex Therapeutics (CLDX) and Quotient (QTNT)Analyzing Celldex Therapeutics (CLDX) and Quotient (QTNT)
www.americanbankingnews.com - May 18 at 3:31 PM
Why Quotient Ltd. Is Soaring TodayWhy Quotient Ltd. Is Soaring Today
www.fool.com - May 18 at 2:40 PM
26 Stocks Moving In Fridays Mid-Day Session26 Stocks Moving In Friday's Mid-Day Session
feeds.benzinga.com - May 18 at 1:09 PM
After-Hours Stock Movers 05/17: (QTNT) (VJET) (AFSI) Higher; (ARQL) (JWN) (AMAT) Lower (more...)After-Hours Stock Movers 05/17: (QTNT) (VJET) (AFSI) Higher; (ARQL) (JWN) (AMAT) Lower (more...)
www.streetinsider.com - May 17 at 6:59 PM
Quotient (QTNT) Commences EU Blood Grouping Field TrialQuotient (QTNT) Commences EU Blood Grouping Field Trial
www.streetinsider.com - May 17 at 6:59 PM
Quotient Limited MosaiQ microarray starting Europe trialsQuotient Limited MosaiQ microarray starting Europe trials
seekingalpha.com - May 17 at 5:28 PM
Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference CallQuotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call
finance.yahoo.com - May 15 at 8:21 AM
The Female Quotient to Host the First Girls Lounge at the 2018 Cannes Film FestivalThe Female Quotient to Host the First Girls' Lounge at the 2018 Cannes Film Festival
www.bizjournals.com - May 11 at 6:03 PM
Intellia Therapeutics (NTLA) and Quotient (QTNT) Critical AnalysisIntellia Therapeutics (NTLA) and Quotient (QTNT) Critical Analysis
www.americanbankingnews.com - May 5 at 1:33 AM
Quotient (QTNT) Upgraded to "Sell" at ValuEngineQuotient (QTNT) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - May 2 at 7:06 PM
Quotient Tech: 1Q Earnings SnapshotQuotient Tech: 1Q Earnings Snapshot
www.cnbc.com - May 2 at 8:17 AM
Achieve Life Sciences (ACHV) & Quotient (QTNT) Head-To-Head AnalysisAchieve Life Sciences (ACHV) & Quotient (QTNT) Head-To-Head Analysis
www.americanbankingnews.com - April 28 at 3:06 AM
Quotient (QTNT) & Its Competitors Critical ContrastQuotient (QTNT) & Its Competitors Critical Contrast
www.americanbankingnews.com - April 27 at 3:32 AM
Contrasting Quotient (QTNT) and The CompetitionContrasting Quotient (QTNT) and The Competition
www.americanbankingnews.com - April 26 at 1:27 PM
Quotient (QTNT) Announces FDA Approval of Seven Blood Bank Reagents, Including Two Market FirstsQuotient (QTNT) Announces FDA Approval of Seven Blood Bank Reagents, Including Two Market Firsts
www.streetinsider.com - April 25 at 5:33 PM
Quotient (QTNT) vs. Its Rivals Head-To-Head SurveyQuotient (QTNT) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - April 21 at 9:08 PM
Quotient (QTNT) versus The Competition Critical AnalysisQuotient (QTNT) versus The Competition Critical Analysis
www.americanbankingnews.com - April 20 at 9:22 PM
Quotient (QTNT) and Its Rivals Head to Head SurveyQuotient (QTNT) and Its Rivals Head to Head Survey
www.americanbankingnews.com - April 14 at 11:33 AM
Reviewing Quotient (QTNT) and Its CompetitorsReviewing Quotient (QTNT) and Its Competitors
www.americanbankingnews.com - April 13 at 3:13 AM
Quotient (QTNT) Upgraded at Zacks Investment ResearchQuotient (QTNT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 12 at 12:33 PM
Critical Contrast: Quotient (QTNT) & Its CompetitorsCritical Contrast: Quotient (QTNT) & Its Competitors
www.americanbankingnews.com - April 12 at 9:51 AM
Critical Review: Quotient (QTNT) versus Its PeersCritical Review: Quotient (QTNT) versus Its Peers
www.americanbankingnews.com - April 10 at 8:18 AM
Quotient (QTNT) Stock Rating Upgraded by Zacks Investment ResearchQuotient (QTNT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 7 at 6:04 PM
Quotient (QTNT) Rating Lowered to Sell at Zacks Investment ResearchQuotient (QTNT) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 4 at 1:53 PM
Quotient (QTNT) PT Lowered to $13.00Quotient (QTNT) PT Lowered to $13.00
www.americanbankingnews.com - April 2 at 11:16 AM
Quotient (QTNT) vs. The Competition Critical ComparisonQuotient (QTNT) vs. The Competition Critical Comparison
www.americanbankingnews.com - March 31 at 11:16 PM
BRIEF-Quotient Announces Retirement Of CEO Paul CowanBRIEF-Quotient Announces Retirement Of CEO Paul Cowan
www.reuters.com - March 26 at 5:23 PM
Quotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback TransactionQuotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction
finance.yahoo.com - March 26 at 5:23 PM
Quotient (QTNT) Stock Rating Upgraded by BidaskClubQuotient (QTNT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 16 at 10:28 PM
Quotient Limited (NASDAQ:QTNT): Does The -11.14% Earnings Drop Reflect A Longer Term Trend?Quotient Limited (NASDAQ:QTNT): Does The -11.14% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - March 13 at 7:22 PM
Prosight Management LP Takes $4.62 Million Position in Quotient Ltd (QTNT)Prosight Management LP Takes $4.62 Million Position in Quotient Ltd (QTNT)
www.americanbankingnews.com - March 5 at 2:55 PM
Hudson Bay Capital Management LP Acquires 435,000 Shares of Quotient Ltd (QTNT)Hudson Bay Capital Management LP Acquires 435,000 Shares of Quotient Ltd (QTNT)
www.americanbankingnews.com - March 2 at 12:48 PM
Quotient Limited to Participate in the Cowen 38th Annual Global Health Care ConferenceQuotient Limited to Participate in the Cowen 38th Annual Global Health Care Conference
finance.yahoo.com - March 1 at 5:55 PM
Prondzynski Heino Von Acquires 12,000 Shares of Quotient Ltd (QTNT) StockProndzynski Heino Von Acquires 12,000 Shares of Quotient Ltd (QTNT) Stock
www.americanbankingnews.com - February 22 at 7:08 PM
Quotient Limited Announces the Sale and Leaseback of its Edinburgh, Scotland Manufacturing and R&D FacilityQuotient Limited Announces the Sale and Leaseback of its Edinburgh, Scotland Manufacturing and R&D Facility
finance.yahoo.com - February 20 at 5:50 PM
Quotient Limited Announces Appointment of Franz Walt as Non-Executive DirectorQuotient Limited Announces Appointment of Franz Walt as Non-Executive Director
finance.yahoo.com - February 20 at 5:50 PM
Brian Mcdonough Purchases 10,000 Shares of Quotient Ltd (QTNT) StockBrian Mcdonough Purchases 10,000 Shares of Quotient Ltd (QTNT) Stock
www.americanbankingnews.com - February 12 at 9:16 PM
Quotient Ltd Expected to Earn FY2018 Earnings of ($2.09) Per Share (QTNT)Quotient Ltd Expected to Earn FY2018 Earnings of ($2.09) Per Share (QTNT)
www.americanbankingnews.com - February 8 at 12:50 PM
Quotient Limited Updates on Status of MosaiQ Performance and Provides Third Quarter Fiscal 2018 Financial ResultsQuotient Limited Updates on Status of MosaiQ Performance and Provides Third Quarter Fiscal 2018 Financial Results
finance.yahoo.com - February 6 at 3:39 PM
Quotient (QTNT) Issues Quarterly  Earnings ResultsQuotient (QTNT) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 5 at 8:32 PM
Quotient Limited to Participate in the LEERINK Partners 7th Annual Global Healthcare ConferenceQuotient Limited to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 31 at 9:10 AM
Quotient (QTNT) Set to Announce Quarterly Earnings on MondayQuotient (QTNT) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - January 29 at 5:30 AM
Quotient Limited to Report Fiscal Third Quarter 2018 Financial Results and Host Conference CallQuotient Limited to Report Fiscal Third Quarter 2018 Financial Results and Host Conference Call
finance.yahoo.com - January 23 at 5:29 PM
Quotient Limited Reports Further Positive Data on its Initial Disease Screening Microarray and Provides Update on Blood GroupingQuotient Limited Reports Further Positive Data on its Initial Disease Screening Microarray and Provides Update on Blood Grouping
finance.yahoo.com - January 9 at 10:58 AM

SEC Filings

Quotient (NASDAQ:QTNT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Quotient (NASDAQ:QTNT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Quotient (NASDAQ QTNT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.